1 unknown. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
Follow Anticoagulation: new trials by email Literature Review of Anticoagulation trials Research Report on Anticoagulation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation Nafamostat Mesylate, Unfractionated Heparin - Critical Illness, Anticoagulation | Phase 2 | Unknown | Xiaobo Yang, MD | 40 | 2022-12-20 | 2023-02-15 |
Critical Illness (1)
Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Heparin (1) · nafamostat (1)
Xiaobo Yang, MD (1)
China (1)